ストックスクリーナーアプリを入手
6.32
6.94%
0.41
アフターアワーズ：
6.36
0.04
+0.63%
前日終値:
$5.91
開ける：
$6.01
24時間の取引高:
182.70K
Relative Volume:
0.95
時価総額：
$340.54M
収益：
-
当期純損益:
$-35.10M
株価収益率:
-8.9633
EPS:
-0.7051
ネットキャッシュフロー:
$-31.49M
1週間 パフォーマンス:
+13.46%
1か月 パフォーマンス:
-0.16%
6か月 パフォーマンス:
-30.70%
1年 パフォーマンス:
+55.67%
1日の値動き範囲:
$5.92
$6.32
1週間の範囲:
$5.501
$6.32
52週間の値動き範囲:
$3.475
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.32 | 318.45M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 開始されました | TD Cowen | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan - The Globe and Mail
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - BioSpace
DiaMedica stroke trial reaches 75% of interim analysis threshold By Investing.com - Investing.com South Africa
DiaMedica stroke trial reaches 75% of interim analysis threshold - Investing.com India
DiaMedica Therapeutics (DMAC) Advances in Pivotal Trial Enrollme - GuruFocus
DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment - marketscreener.com
Why Is DiaMedica Therapeutics Inc. (DMAC) Stock Down Today? - Meyka
TradingKey - TradingKey
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
MSN Money - MSN
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2026 Earnings Call Transcript - insidermonkey.com
DiaMedica (DMAC) Q1 2026 Earnings Transcript - AOL.com
Why DiaMedica (DMAC) deserves a deeper look right now (Bearish Sentiment) 2026-05-08Social Investment Platform - newser.com
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : DiaMedica Therapeutics Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
DiaMedica Therapeutics Q1 Earnings Call Highlights - Barchart.com
DiaMedica Therapeutics Inc. Q1 2026 Financial Results, Clinical Trial Updates, and Forward-Looking Statements - Minichart
Earnings call transcript: DiaMedica Therapeutics Q1 2026 results show R&D focus - Investing.com
DMAC: DM199 trials progress in preeclampsia and stroke, with strong cash position and key data ahead - TradingView
Diamedica Therapeutics Inc. (DMAC) Files Form 8-K with Financial Statements and Company Information for May 2026 - Minichart
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience - ChartMill
[10-Q] DiaMedica Therapeutics Inc. Quarterly Earnings Report - Stock Titan
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Higher R&D drives DiaMedica (NASDAQ: DMAC) wider Q1 2026 loss - Stock Titan
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - BioSpace
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
DMAC Price Today: DiaMedica Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading.Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh
Is DiaMedica (DMAC) stock worth committing funds to (Drifts Higher) 2026-04-22Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):